Literature DB >> 25394662

Increased gastrin gene expression provides a physiological advantage to mice under hypoxic conditions.

Marie Laval1, Graham S Baldwin1, Arthur Shulkes1, Kathryn M Marshall2.   

Abstract

Hypoxia, or a low concentration of O2, is encountered in humans undertaking activities such as mountain climbing and scuba diving and is important pathophysiologically as a limiting factor in tumor growth. Although data on the interplay between hypoxia and gastrins are limited, gastrin expression is upregulated by hypoxia in gastrointestinal cancer cell lines, and gastrins counterbalance hypoxia by stimulating angiogenesis in vitro and in vivo. The aim of this study was to determine if higher concentrations of the gastrin precursor progastrin are protective against hypoxia in vivo. hGAS mice, which overexpress progastrin in the liver, and mice of the corresponding wild-type FVB/N strain were exposed to normoxia or hypoxia. Iron status was assessed by measurement of serum iron parameters, real-time PCR for mRNAs encoding critical iron regulatory proteins, and Perls' stain and atomic absorption spectrometry for tissue iron concentrations. FVB/N mice lost weight at a faster rate and had higher sickness scores than hGAS mice exposed to hypoxia. Serum iron levels were lower in hGAS than FVB/N mice and decreased further when the animals were exposed to hypoxia. The concentration of iron in the liver was strikingly lower in hGAS than FVB/N mice. We conclude that increased circulating concentrations of progastrin provide a physiological advantage against systemic hypoxia in mice, possibly by increasing the availability of iron stores. This is the first report of an association between progastrin overexpression, hypoxia, and iron homeostasis.
Copyright © 2015 the American Physiological Society.

Entities:  

Keywords:  gastrin; hypoxia; iron

Mesh:

Substances:

Year:  2014        PMID: 25394662     DOI: 10.1152/ajpgi.00344.2014

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  3 in total

1.  Gastrin exerts a protective effect against myocardial infarction via promoting angiogenesis.

Authors:  Jinjuan Fu; Yuanjuan Tang; Zhen Zhang; Lin Tong; Rongchuan Yue; Lin Cai
Journal:  Mol Med       Date:  2021-08-19       Impact factor: 6.354

2.  Gastrin Protects Against Myocardial Ischemia/Reperfusion Injury via Activation of RISK (Reperfusion Injury Salvage Kinase) and SAFE (Survivor Activating Factor Enhancement) Pathways.

Authors:  Xiaoli Yang; Rongchuan Yue; Jun Zhang; Xiaoqun Zhang; Yukai Liu; Caiyu Chen; Xinquan Wang; Hao Luo; Wei Eric Wang; Xiongwen Chen; Huixia Judy Wang; Pedro A Jose; Hongyong Wang; Chunyu Zeng
Journal:  J Am Heart Assoc       Date:  2018-07-12       Impact factor: 5.501

3.  Gastrin mediates cardioprotection through angiogenesis after myocardial infarction by activating the HIF-1α/VEGF signalling pathway.

Authors:  Rui Wang; Ziyue Zhang; Zaicheng Xu; Na Wang; Dezhong Yang; Zhi Zhao Liu; Qiao Liao; Xuewei Xia; Caiyu Chen; Jialing Shou; Liangpeng Li; Wei Eric Wang; Chunyu Zeng; Tianyang Xia; Hongyong Wang
Journal:  Sci Rep       Date:  2021-08-04       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.